KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Cash: 2011-2025

Historic Change in Cash for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $100.0 million.

  • Sarepta Therapeutics' Change in Cash rose 153.84% to $100.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $412.8 million, marking a year-over-year increase of 218.73%. This contributed to the annual value of $674.6 million for FY2024, which is 224.51% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Change in Cash stood at $100.0 million for Q3 2025, which was down 62.92% from $269.7 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Change in Cash high stood at $905.2 million for Q4 2024, and its period low was -$882.0 million during Q1 2022.
  • In the last 3 years, Sarepta Therapeutics' Change in Cash had a median value of -$43.7 million in 2024 and averaged -$32.7 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Change in Cash skyrocketed by 1,714.55% in 2021 and then tumbled by 75,526.58% in 2025.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Change in Cash stood at $517.3 million in 2021, then plummeted by 113.89% to -$71.8 million in 2022, then crashed by 62.95% to -$117.1 million in 2023, then surged by 873.16% to $905.2 million in 2024, then soared by 153.84% to $100.0 million in 2025.
  • Its last three reported values are $100.0 million in Q3 2025, $269.7 million for Q2 2025, and -$862.1 million during Q1 2025.